Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $18.75 Average Price Target from Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $18.75.

Several research analysts have issued reports on the stock. JPMorgan Chase & Co. dropped their target price on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, June 25th. Chardan Capital restated a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a report on Monday, May 11th. Weiss Ratings raised shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 10th. Finally, Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th.

Lexeo Therapeutics Trading Up 4.5%

Shares of LXEO stock opened at $4.87 on Thursday. Lexeo Therapeutics has a twelve month low of $3.60 and a twelve month high of $10.99. The stock has a market capitalization of $382.39 million, a price-to-earnings ratio of -3.36 and a beta of 1.42. The stock has a fifty day simple moving average of $4.77 and a two-hundred day simple moving average of $6.07.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. Research analysts predict that Lexeo Therapeutics will post -1.21 EPS for the current fiscal year.

Insider Buying and Selling

In other Lexeo Therapeutics news, insider Narinder Pal Bhalla sold 22,306 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total transaction of $98,592.52. Following the sale, the insider owned 82,194 shares of the company’s stock, valued at approximately $363,297.48. This trade represents a 21.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total value of $116,242.56. Following the completion of the transaction, the chief executive officer owned 377,817 shares in the company, valued at $1,692,620.16. This represents a 6.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 62,204 shares of company stock valued at $280,089 in the last three months. 2.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of institutional investors have recently added to or reduced their stakes in LXEO. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Lexeo Therapeutics by 69.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after purchasing an additional 1,459 shares in the last quarter. Bank of America Corp DE increased its position in Lexeo Therapeutics by 6.1% during the 3rd quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock valued at $188,000 after buying an additional 1,626 shares in the last quarter. California State Teachers Retirement System increased its position in Lexeo Therapeutics by 123.7% during the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after buying an additional 2,148 shares in the last quarter. Intech Investment Management LLC raised its stake in Lexeo Therapeutics by 19.5% in the fourth quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock valued at $141,000 after buying an additional 2,317 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Lexeo Therapeutics by 25.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,893 shares of the company’s stock valued at $118,000 after buying an additional 2,427 shares during the last quarter. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.